If you have been reading about animal models and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
He found that he could extract some pigments (such as orange carotenes and yellow xanthophylls) from leaves with non-polar solvents, but others (such as chlorophyll) required polar solvents. He reasoned that chlorophyll was held to the plant tissue by adsorption, and that stronger solvents were necessary to overcome the adsorption. To test this, he applied dissolved pigments to filter paper, allowed the solvent to evaporate, then applied different solvents to see which could extract the pigments from the filter paper. He found the same pattern as from leaf extractions: carotene could be extracted from filter paper using non-polar solvents, but chlorophyll required polar solvents. Tsvet's work saw little use until the 1930s.
=== Prevention === A migraine management plan often includes lifestyle modifications to cope with migraine triggers and reduce the impact of comorbidities. Recommended lifestyle modifications support a consistent lifestyle, through regular sleep patterns, regular eating, staying hydrated, managing stress, engaging in moderate exercise, and maintaining a healthy body weight. Avoiding dietary triggers and caffeine overuse may also be recommended. Improving sleep patterns may be particularly helpful in reducing migraine frequency for adults with chronic migraines. Behavioral techniques that have been used in the treatment of migraines include Cognitive Behavioral Therapy (CBT), relaxation training, biofeedback, acceptance and commitment therapy (ACT), as well as mindfulness-based therapies. These treatments can reduce migraine frequency both on their own and in combination with other treatment options. For children and adolescents, CBT and biofeedback strategies are effective in decreasing the frequency and intensity of migraines. These techniques often include relaxation methods and promotion of long-term management without medication side effects, which is emphasized for younger individuals. A variety of possible diets have been proposed, including ketogenic diet, Mediterranean diet, DASH diet, and high intakes of fruits, vegetables, legumes, and oil seeds. Evidence supporting interventions such as transcranial magnetic stimulation and transcutaneous supraorbital nerve stimulation remains limited.
Emus forage in a diurnal pattern and eat a variety of native and introduced plant species. The diet depends on seasonal availability with such plants as Acacia, Casuarina and grasses being favoured. They also eat insects and other arthropods, including grasshoppers and crickets, beetles, cockroaches, ladybirds, bogong and cotton-boll moth larvae, ants, spiders and millipedes. This provides a large part of their protein requirements. In Western Australia, food preferences have been observed in travelling emus; they eat seeds from Acacia aneura until the rains arrive, after which they move on to fresh grass shoots and caterpillars; in winter they feed on the leaves and pods of Cassia and in spring, they consume grasshoppers and the fruit of Santalum acuminatum, a sort of quandong. They are also known to feed on wheat, and any fruit or other crops that they can access, easily climbing over high fences if necessary. Emus serve as an important agent for the dispersal of large viable seeds, which contributes to floral biodiversity. One undesirable effect of this occurred in Queensland in the early twentieth century when emus fed on the fruit of prickly pears in the outback. They defecated the seeds in various places as they moved around, and this led to a series of campaigns to hunt emus and prevent the seeds of the invasive cactus being spread. The cacti were eventually controlled by an introduced moth (Cactoblastis cactorum) whose larvae fed on the plant, one of the earliest examples of biological control.
Building automation, access control, smart energy — DASH7's signal propagation characteristics allow it to penetrate walls, windows, doors, and other substances that serve as impediments to other technologies operating at 2.45 GHz, for example. For smart energy and building automation applications, DASH7 networks can be deployed with far less infrastructure than competing technologies and at far lower total cost of ownership. Location-based services — DASH7 is being used today for developing new location-based services using a range of DASH7-enabled devices, including smartcards, keyfobs, tickets, watches and other conventional products that can take advantage of the unique small footprint, low power, long range, and low cost of DASH7 relative to less practical and high-power wireless technologies like Wi-Fi or Bluetooth. Using DASH7, users can "check in" to venues in ways not practical with current check-in technologies like GPS, that are power-intensive and fail indoors and in urban environments. Location-based services like Foursquare, Novitaz, or Facebook can exploit this capability in DASH7 and award loyalty points, allow users to view the Facebook or X, formally known as Twitter, addresses of those walking past, and more. Mobile advertising — DASH7 is being developed for "smart" billboards and kiosks, likewise "smart" posters that can be read from many meters (or even kilometers) away, creating new opportunities for both tracking the effectiveness of advertising expenditures, but also creating new e-commerce opportunities.
Sources: en.wikipedia.org
== Examples == Inflammation is usually indicated by adding the suffix "itis", as shown below. However, some conditions, such as asthma and pneumonia, do not follow this convention. More examples are available at List of types of inflammation.
== Modifications == The ribonucleosides adenosine, cytidine, guanosine, and uridine are all derivatives of β-d-ribofuranose. Metabolically important species that include phosphorylated ribose include ADP, ATP, coenzyme A, and NADH. cAMP and cGMP serve as secondary messengers in some signaling pathways and are also ribose derivatives. The ribose moiety appears in some pharmaceutical agents, including the antibiotics neomycin and paromomycin.
Integral polytopic proteins are transmembrane proteins that span across the membrane more than once. These proteins may have different transmembrane topology. These proteins have one of two structural architectures: Helix bundle proteins, which are present in all types of biological membranes; Beta barrel proteins, which are found only in outer membranes of Gram-negative bacteria, and outer membranes of mitochondria and chloroplasts. Bitopic proteins are transmembrane proteins that span across the membrane only once. Transmembrane helices from these proteins have significantly different amino acid distributions to transmembrane helices from polytopic proteins. Integral monotopic proteins are integral membrane proteins that are attached to only one side of the membrane and do not span the whole way across.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.